Social Media Ideas for Biopharmaceutical

<![CDATA[Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change]]>

<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Biopharma Hungry for GLP-1 Receptor Agonist Manufacturing Skills

NIBRT predicts that the market for GLP-1 receptor agonist-based diabetes and obesity meds will increase demand for biopharmaceutical engineers with a mix of synthetic chemistry and...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

<![CDATA[What Would a Category One Designation Mean for Peptides?]]>

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

<![CDATA[Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321 ]]>

AI Protein Engineering Model Designed for Biomanufacturing

Generating biomanufacturing-relevant data on protein production in a large-scale, AI-enabled database is still rare. When commercialized, it may substantially improve development t...

<![CDATA[What FDA's Peptide Decision Means for the Industry]]>

<![CDATA[Nuvation Bio’s Global Strategy]]>

Celonic and Leukocare Collaborate to Support Complex Biologics and Advanced Drug Development

The collaboration brings together Celonic’s expertise in cell line development, drug substance process development, intensified bioprocessing, and GMP manufacturing with Leukocare’...

<![CDATA[Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera]]>

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

<![CDATA[Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech]]>

Indiana Emerges as a Leading U.S. Biopharma Hub

Indiana has spent decades becoming a national leader in life sciences and pharmaceutical exports. Its strengths extend across universities, research institutes, manufacturers, supp...

Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production

To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...

<![CDATA[Your Questions Answered: The Biggest Pharma and Biotech Stories This Week]]>

<![CDATA[Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals]]>

Streamlining stable cell line development from the start

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks. The post Streamlining stable cell line development from th...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik]]>

<![CDATA[The Path from Discovery to Global Commercialization]]>

Biocon sees stronger H2 on US biosimilar launches, regulatory easing

The US regulator’s decision to move away from subjecting companies to undertake mandatory efficacy trials in phase-3 bodes well for incumbents such as Biocon